Marcel O Bonn-Miller1, Megan Brunstetter2, Alex Simonian2, Mallory J Loflin3,4, Ryan Vandrey5, Kimberly A Babson6, Hal Wortzel7,8. 1. Perelman School of Medicine, The University of Pennsylvania, Philadelphia, Pennsylvania, USA. 2. Denver Research Institute, Denver, Colorado, USA. 3. VA San Diego Health Care System, Center of Excellence for Stress and Mental Health and National Center for PTSD, San Diego, California, USA. 4. University of California San Diego School of Medicine, La Jolla, California, USA. 5. Johns Hopkins School of Medicine, Baltimore, Maryland, USA. 6. VA Palo Alto Health Care System, Menlo Park, California, USA. 7. Rocky Mountain MIRECC Rocky, Rocky Mountain Regional VA Medical Center, Aurora, Colorado, USA. 8. University of Colorado School of Medicine, Aurora, Colorado, USA.
Abstract
Introduction: Given the increasing availability and use of cannabis among individuals with post-traumatic stress disorder (PTSD) and the addition of PTSD as an eligible diagnosis in several U.S. medical cannabis programs, the efficacy of dispensary-obtained cannabis needs to be thoroughly examined. Materials and Methods: This prospective study assessed PTSD symptoms and functioning every 3 months over the course of a year in two samples of participants diagnosed with PTSD: (1) those with PTSD using dispensary-obtained cannabis (cannabis users) and (2) those with PTSD, who do not use cannabis (controls). Linear mixed-effects models and generalized estimating equations tested whether trajectories of symptoms differed between the two subsamples. Results: A total of 150 participants (mean [standard deviation] age, 50.67 [15.26] years; 73% male) were enrolled in the study. Over the course of 1 year, the cannabis users reported a greater decrease in PTSD symptom severity over time compared to controls [group×time interaction=-0.32 (95% confidence interval [CI]=-0.59 to -0.05, R2=0.13; t=-2.35, p=0.02). Participants who used cannabis were 2.57 times more likely to no longer meet DSM-5 criteria for PTSD at the end of the study observation period compared to participants who did not use cannabis (95% CI=1.12-6.07; p=0.03). Conclusions: This study provides evidence that the types of cannabis available in recreational and medical cannabis dispensaries might hold promise as an alternative treatment for PTSD. Randomized placebo-controlled trials are needed to assess safety and determine how different preparations of cannabis impact PTSD and functioning.
Introduction: Given the increasing availability and use of cannabis among individuals with post-traumatic stress disorder (PTSD) and the addition of PTSD as an eligible diagnosis in several U.S. medical cannabis programs, the efficacy of dispensary-obtained cannabis needs to be thoroughly examined. Materials and Methods: This prospective study assessed PTSD symptoms and functioning every 3 months over the course of a year in two samples of participants diagnosed with PTSD: (1) those with PTSD using dispensary-obtained cannabis (cannabis users) and (2) those with PTSD, who do not use cannabis (controls). Linear mixed-effects models and generalized estimating equations tested whether trajectories of symptoms differed between the two subsamples. Results: A total of 150 participants (mean [standard deviation] age, 50.67 [15.26] years; 73% male) were enrolled in the study. Over the course of 1 year, the cannabis users reported a greater decrease in PTSD symptom severity over time compared to controls [group×time interaction=-0.32 (95% confidence interval [CI]=-0.59 to -0.05, R2=0.13; t=-2.35, p=0.02). Participants who used cannabis were 2.57 times more likely to no longer meet DSM-5 criteria for PTSD at the end of the study observation period compared to participants who did not use cannabis (95% CI=1.12-6.07; p=0.03). Conclusions: This study provides evidence that the types of cannabis available in recreational and medical cannabis dispensaries might hold promise as an alternative treatment for PTSD. Randomized placebo-controlled trials are needed to assess safety and determine how different preparations of cannabis impact PTSD and functioning.
Authors: Mallory J E Loflin; Kimberly Babson; James Sottile; Sonya B Norman; Staci Gruber; Marcel O Bonn-Miller Journal: Am J Drug Alcohol Abuse Date: 2019-05-28 Impact factor: 3.829
Authors: A Batalla; J A Crippa; G F Busatto; F S Guimaraes; A W Zuardi; O Valverde; Z Atakan; P K McGuire; S Bhattacharyya; R Martín-Santos Journal: Curr Pharm Des Date: 2014 Impact factor: 3.116
Authors: Justin Thomas Fischedick; Arno Hazekamp; Tjalling Erkelens; Young Hae Choi; Rob Verpoorte Journal: Phytochemistry Date: 2010-10-30 Impact factor: 4.072
Authors: Frank W Weathers; Michelle J Bovin; Daniel J Lee; Denise M Sloan; Paula P Schnurr; Danny G Kaloupek; Terence M Keane; Brian P Marx Journal: Psychol Assess Date: 2017-05-11
Authors: Fabricio H Do Monte; Rimenez R Souza; Rafael M Bitencourt; Juliana A Kroon; Reinaldo N Takahashi Journal: Behav Brain Res Date: 2013-05-01 Impact factor: 3.332
Authors: Bhanu Prakash Kolla; Lisa Hayes; Chaun Cox; Lindy Eatwell; Mark Deyo-Svendsen; Meghna P Mansukhani Journal: J Prim Care Community Health Date: 2022 Jan-Dec
Authors: Albert Garcia-Romeu; Joshua Elmore; Rhiannon E Mayhugh; Nicolas J Schlienz; Erin L Martin; Justin C Strickland; Marcel Bonn-Miller; Heather Jackson; Ryan Vandrey Journal: Front Pharmacol Date: 2022-09-06 Impact factor: 5.988